(Q56765596)

English

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Cesare Gridelli

17

object named as

Cesare Gridelli

0 references

author name string

Luis Paz-Ares

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Filippo de Marinis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Mircea Dediu

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Michael Thomas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Jean-Louis Pujol

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Paolo Bidoli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Olivier Molinier

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Tarini Prasad Sahoo

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Eckart Laack

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Martin Reck

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Jesús Corral

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Symantha Melemed

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

William John

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Nadia Chouaki

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Annamaria H Zimmermann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Carla Visseren-Grul

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Cesare Gridelli

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

16 February 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

247-255

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing first-line treatment options for patients with advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970063-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70063-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22341744%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56765596&oldid=1584466602"